Skip to content
Remodulin, Trepulmix(treprostinil palmitil)
Orenitram, Remodulin, Trepulmix, Tyvaso (treprostinil palmitil) is a small molecule pharmaceutical. Treprostinil palmitil was first approved as Remodulin on 2002-05-21. It has been approved in Europe to treat pulmonary hypertension.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
respiratory tract diseasesD012140
cardiovascular diseasesD002318
Trade Name
FDA
EMA
Orenitram, Remodulin, Tyvaso, Tyvaso dpi (generic drugs available since 2017-11-30)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Treprostinil
Tradename
Company
Number
Date
Products
REMODULINUnited TherapeuticsN-021272 RX2002-05-21
5 products, RLD, RS
TYVASOUnited TherapeuticsN-022387 RX2009-07-30
1 products, RLD, RS
TYVASO DPIUnited TherapeuticsN-214324 RX2022-05-23
4 products, RLD, RS
Show 1 discontinued
Treprostinil diolamine
Tradename
Company
Number
Date
Products
ORENITRAMUnited TherapeuticsN-203496 RX2013-12-20
5 products, RLD
Labels
FDA
EMA
Brand Name
Status
Last Update
diluent treprostinilANDA2023-04-06
orenitramNew Drug Application2022-01-06
remodulin sterile diluent for remodulinNew Drug Application2022-03-31
tyvasoNew Drug Application2022-09-12
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration
Code
TREPROSTINIL DIOLAMINE, ORENITRAM, UNITED THERAP
2026-10-18ODE-272
TREPROSTINIL, TYVASO, UNITED THERAP
2024-03-31I-856
Patent Expiration
Patent
Expires
Flag
FDA Information
Treprostinil, Tyvaso Dpi, United Therap
104217292035-04-01DP
107728832030-06-11DP
101306852025-08-23DP
Treprostinil Diolamine, Orenitram, United Therap
87478972031-08-11DPU-2724, U-2725
83498922031-01-22DP
84101692030-02-13DP
84973932028-12-15DP
74170702026-07-30DP
93932032026-04-27DPU-1877
75447132024-07-14U-1475
82528392024-05-24DP
90503112024-05-24DS, DP
92789012024-05-24U-1475
94222232024-05-24DP
Treprostinil, Remodulin, United Therap
79990072029-03-29DPU-1437
95930662028-12-15DP
96049012028-12-15DP
86531372028-09-05U-1437
86586942028-09-05U-1437
97135992024-12-16U-2036
100765052024-12-16DP
106953082024-12-16U-2845
91999082024-05-24U-1771
Treprostinil, Tyvaso, United Therap
93582402028-05-05U-1849
93395072028-03-10DP
103765252027-05-14U-1849
107167932027-05-14U-1849
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
109 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Pulmonary arterial hypertensionD000081029109912645
Pulmonary hypertensionD006976EFO_0001361I27.20310156233
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Interstitial lung diseasesD017563EFO_0004244J84.89—66—110
Chronic obstructive pulmonary diseaseD029424EFO_0000341J44.9122——5
Idiopathic pulmonary fibrosisD054990J84.112—23——5
Pulmonary fibrosisD011658J84.10—32—14
IschemiaD007511EFO_0000556—21——3
Familial primary pulmonary hypertensionD065627I27.0——2——2
Peripheral vascular diseasesD016491EFO_0003875I73.9—12——2
Heart failureD006333EFO_0003144I50——1——1
Liver transplantationD016031EFO_0010682—11——1
Foot ulcerD016523——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Systemic sclerodermaD012595EFO_0000717M3435———6
Healthy volunteers/patients—51———5
Reperfusion injuryD01542722———2
Congenital heart defectsD006330HP_0001627Q24.9—1——12
Delayed graft functionD05179911———1
SarcoidosisD012507EFO_0000690D80-D89—1———1
Diabetic footD017719EFO_100145911———1
CalcinosisD002114—1———1
Respiratory distress syndromeD012128EFO_1000637J80—1———1
Persistent fetal circulation syndromeD010547EFO_1001103P29.3—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Raynaud diseaseD011928EFO_1001145I73.01————1
Type 1 diabetes mellitusD003922EFO_0001359E101————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameTREPROSTINIL PALMITIL
INNtreprostinil palmitil
Description
Orenitram, Remodulin, Trepulmix, Tyvaso (treprostinil palmitil) is a small molecule pharmaceutical. Treprostinil palmitil was first approved as Remodulin on 2002-05-21. It has been approved in Europe to treat pulmonary hypertension.
Classification
Small molecule
Drug classprostaglandins
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CCCCCCCCCCCCCCCCOC(=O)COc1cccc2c1C[C@H]1C[C@@H](O)[C@H](CC[C@@H](O)CCCCC)[C@H]1C2
Identifiers
PDB—
CAS-ID1706528-83-7
RxCUI—
ChEMBL IDCHEMBL4650232
ChEBI ID—
PubChem CID—
DrugBank—
UNII ID8GJK87S89F (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Remodulin - United Therapeutics
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Orenitram - United Therapeutics
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tyvaso - United Therapeutics
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 2,091 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
62,034 adverse events reported
View more details